These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 15295679)
21. Verteporfin and intravitreal triamcinolone acetonide combination therapy for occult choroidal neovascularization in age-related macular degeneration. Augustin AJ; Schmidt-Erfurth U Am J Ophthalmol; 2006 Apr; 141(4):638-45. PubMed ID: 16564797 [TBL] [Abstract][Full Text] [Related]
22. Anecortave acetate (15 milligrams) versus photodynamic therapy for treatment of subfoveal neovascularization in age-related macular degeneration. Slakter JS; Bochow TW; D'Amico DJ; Marks B; Jerdan J; Sullivan EK; Robertson SM; Slakter JS; Sullins G; Zilliox P; Ophthalmology; 2006 Jan; 113(1):3-13. PubMed ID: 16368146 [TBL] [Abstract][Full Text] [Related]
23. Choroidal neovascularization complicating photodynamic therapy for central serous retinopathy. Colucciello M Retina; 2006 Feb; 26(2):239-42. PubMed ID: 16467692 [No Abstract] [Full Text] [Related]
24. Photodynamic therapy with intravitreal triamcinolone in predominantly classic choroidal neovascularization: one-year results of a randomized study. Arias L; Garcia-Arumi J; Ramon JM; Badia M; Rubio M; Pujol O Ophthalmology; 2006 Dec; 113(12):2243-50. PubMed ID: 16996600 [TBL] [Abstract][Full Text] [Related]
33. Randomized multicenter trial of more intense and standard early verteporfin treatment of neovascular age-related macular degeneration. Schmidt-Erfurth U; Sacu S; Ophthalmology; 2008 Jan; 115(1):134-40. PubMed ID: 18166408 [TBL] [Abstract][Full Text] [Related]
34. Photodynamic therapy with verteporfin in patients with age-related macular degeneration and juxtafoveal choroidal neovascularization. Frennesson CI Acta Ophthalmol Scand; 2004 Dec; 82(6):651-5. PubMed ID: 15606459 [TBL] [Abstract][Full Text] [Related]
35. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial. Azab M; Boyer DS; Bressler NM; Bressler SB; Cihelkova I; Hao Y; Immonen I; Lim JI; Menchini U; Naor J; Potter MJ; Reaves A; Rosenfeld PJ; Slakter JS; Soucek P; Strong HA; Wenkstern A; Su XY; Yang YC; Arch Ophthalmol; 2005 Apr; 123(4):448-57. PubMed ID: 15824216 [TBL] [Abstract][Full Text] [Related]
36. Increased and persisted subretinal haemorrhage after photodynamic therapy for choroidal neovascularization secondary to angioid streaks. Shyong MP; Chen SJ; Lee FL; Tsao YP; Hsu WM Eye (Lond); 2006 Dec; 20(12):1420-2. PubMed ID: 16645630 [No Abstract] [Full Text] [Related]
37. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration. Dhalla MS; Shah GK; Blinder KJ; Ryan EH; Mittra RA; Tewari A Retina; 2006; 26(9):988-93. PubMed ID: 17151484 [TBL] [Abstract][Full Text] [Related]
38. Limited macular translocation compared with photodynamic therapy in the management of subfoveal choroidal neovascularization in age-related macular degeneration. Pawlak D; Glacet-Bernard A; Papp M; Roquet W; Coscas G; Soubrane G Am J Ophthalmol; 2004 May; 137(5):880-7. PubMed ID: 15126153 [TBL] [Abstract][Full Text] [Related]
39. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. Heier JS; Boyer DS; Ciulla TA; Ferrone PJ; Jumper JM; Gentile RC; Kotlovker D; Chung CY; Kim RY; Arch Ophthalmol; 2006 Nov; 124(11):1532-42. PubMed ID: 17101999 [TBL] [Abstract][Full Text] [Related]